ATE469174T1 - Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung - Google Patents

Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung

Info

Publication number
ATE469174T1
ATE469174T1 AT05815961T AT05815961T ATE469174T1 AT E469174 T1 ATE469174 T1 AT E469174T1 AT 05815961 T AT05815961 T AT 05815961T AT 05815961 T AT05815961 T AT 05815961T AT E469174 T1 ATE469174 T1 AT E469174T1
Authority
AT
Austria
Prior art keywords
peptides
shaped
amphipathic helix
amphipathic
disclosed
Prior art date
Application number
AT05815961T
Other languages
English (en)
Inventor
Alan T Remaley
Stephen J Demosky
John A Stonik
Marcele J Amar
Edward B Neufeld
H Brewer
Fairwell Thomas
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE469174T1 publication Critical patent/ATE469174T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AT05815961T 2004-10-15 2005-10-14 Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung ATE469174T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61939204P 2004-10-15 2004-10-15
PCT/US2005/036933 WO2006044596A2 (en) 2004-10-15 2005-10-14 Multi-domain amphipathic helical peptides and methods of their use

Publications (1)

Publication Number Publication Date
ATE469174T1 true ATE469174T1 (de) 2010-06-15

Family

ID=36203530

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05815961T ATE469174T1 (de) 2004-10-15 2005-10-14 Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung

Country Status (9)

Country Link
US (4) US7572771B1 (de)
EP (2) EP2218736A1 (de)
JP (1) JP5091679B2 (de)
AT (1) ATE469174T1 (de)
AU (1) AU2005295640B2 (de)
CA (1) CA2584048C (de)
DE (1) DE602005021534D1 (de)
ES (1) ES2346771T3 (de)
WO (1) WO2006044596A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20110059549A1 (en) 2007-05-09 2011-03-10 Coleman Matthew A Methods and systems for producing nanolipoprotein particles
US8936787B2 (en) 2008-04-15 2015-01-20 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptides promoting lipid efflux
WO2010020822A1 (en) * 2008-08-19 2010-02-25 University Of Patras Therapy for apolipoprotein-induced hypertriglyceridemia
US10151037B2 (en) 2009-01-12 2018-12-11 Lawrence Livermore National Security, Llc Electrochemical flow-cell for hydrogen production and nicotinamide dependent target reduction, and related methods and systems
WO2011066511A1 (en) 2009-11-30 2011-06-03 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof
JP2014518620A (ja) * 2011-04-26 2014-08-07 モレキュラー エクスプレス，インコーポレイテッド リポソーム製剤
EP2701725A1 (de) 2011-04-29 2014-03-05 Kinemed, Inc. Chemische modifizierung von mimetischen apolipoproteinpeptiden zur herstellung von therapeutika
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
AU2013299641A1 (en) 2012-08-10 2015-03-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids
WO2014028895A1 (en) 2012-08-16 2014-02-20 Synthetic Genomics, Inc. Digital to biological converter
WO2015057583A1 (en) 2013-10-14 2015-04-23 The United States Of America, As Represented By The Secretary Treatment of chronic kidney disease with sahps
SG11201609084QA (en) 2014-05-02 2016-11-29 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
US11529390B2 (en) * 2015-03-19 2022-12-20 Institut De Cardiologie De Montreal PCSK9 inhibitory polypolypeptides and methods of use
US11279749B2 (en) 2015-09-11 2022-03-22 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
WO2018019911A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sarl Therapeutic combinations to treat red blood cell disorders
US11207422B2 (en) 2017-05-02 2021-12-28 Lawrence Livermore National Security, Llc MOMP telonanoparticles, and related compositions, methods and systems
US20200102356A1 (en) * 2018-10-01 2020-04-02 NMC Inc. Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
DE3436928A1 (de) * 1984-10-09 1986-04-10 Siegel, Rolf, Dr., 8700 Würzburg Alloplastische gefaessprothese, verfahren zu deren herstellung
EP0206448B1 (de) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hämoglobin, das an ein Poly(alkenylenoxid) gebunden ist
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
WO1993025581A1 (en) 1992-06-12 1993-12-23 N.V. Innogenetics S.A. New peptides and proteins, process for their preparation and their use as cholesterol acceptors
AU6059898A (en) * 1996-09-05 1998-03-26 Uab Research Foundation, The Anti-atherosclerotic peptides and a transgenic mouse model of atherosclerosis
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US7205280B2 (en) 1998-03-11 2007-04-17 Cognosci, Inc. Methods of suppressing microglial activation
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
JP2003529375A (ja) 2000-03-31 2003-10-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヒト動脈壁細胞内で酸化脂質により誘発される遺伝子の制御
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
CN104558200B (zh) 2004-09-02 2021-11-16 康石医药科技（上海）有限公司 改进的apo e类似物及其使用方法
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US8710429B2 (en) 2007-12-21 2014-04-29 The Board Of Regents Of The University Of Ok Identification of biomarkers in biological samples and methods of using same

Also Published As

Publication number Publication date
US7572771B1 (en) 2009-08-11
US8835378B2 (en) 2014-09-16
CA2584048A1 (en) 2006-04-27
EP1812474A2 (de) 2007-08-01
WO2006044596A3 (en) 2006-09-08
US20120148642A1 (en) 2012-06-14
JP2008516605A (ja) 2008-05-22
AU2005295640A1 (en) 2006-04-27
US8148323B2 (en) 2012-04-03
AU2005295640B2 (en) 2011-07-28
ES2346771T3 (es) 2010-10-20
EP2218736A1 (de) 2010-08-18
CA2584048C (en) 2016-08-09
WO2006044596A8 (en) 2006-06-29
DE602005021534D1 (de) 2010-07-08
WO2006044596A2 (en) 2006-04-27
EP1812474B1 (de) 2010-05-26
US20090270331A1 (en) 2009-10-29
AU2005295640A2 (en) 2006-04-27
JP5091679B2 (ja) 2012-12-05
US20100203099A1 (en) 2010-08-12
US8071746B2 (en) 2011-12-06

Similar Documents

Publication Publication Date Title
ATE469174T1 (de) Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
Li et al. A small-molecule TrkB ligand restores hippocampal synaptic plasticity and object location memory in Rett syndrome mice
Franklin et al. The prevalence of epigenetic mechanisms in the regulation of cognitive functions and behaviour
CY1124111T1 (el) Παραγοντες ρυθμισης γλουταμικου στην αντιμετωπιση ψυχικων διαταραχων
DE602004022424D1 (de) Proteasominhibitoren und verfahren zu deren anwendung
ATE517638T1 (de) Verfahren und zubereitungen zum verabreichen von therapeutischen und diagnostischen mitteln
ATE498395T1 (de) Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung
BRPI0715718A2 (pt) Anticorpo, métodos de triar para um anticorpo para o domínio extracelular de uma proteína prlr, de alterar sistematicamente anticorpos e triar para um anticorpo para o domínio extracelular de uma proteína prlr, de tratar um indivíduo que sofre de câncer, de alvejar uma célula tumoral que expressa prlr, de usar uma célula hospedeira, de identificar um indivíduo com necessidade de tratamento com um anticorpo anti-prlr, e de monitorar terapia de câncer em um indivíduo, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, composição farmacêutica, e, kit
EP2453024A3 (de) Differenziell exprimierte Gene und Leitungsbahnen bei bipolarer Störung und/oder schwerer depressiver Erkrankung
WO2006112705A3 (en) Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure.
ATE404188T1 (de) Verfahren und zusammensetzungen zur behandlung von augenerkrankungen mit retinyl-derivaten
DE602006012513D1 (de) Verfahren zur behandlung von kopfschmerzen durch verabreichung von oxytocin
DE602005007373D1 (de) IDENTIFIKATION UND VERWENDUNG VON miRNAs ZUR DIFFERENZIERUNG MYELOGENER LEUKÄMIEZELLEN
WO2003089457A3 (en) Peptide inhibitors of protein kinase c ϝ for pain management
DE60208278D1 (de) System und Verfahren zum Testen von Nukleinsäuremolekülen
DE60027551D1 (de) Zusammensetzungen und verfahren zur regulierung des serumcholesterins
ATE398921T1 (de) Modulare anordnung und verfahren zum züchten von wassertieren
DE602005000485D1 (de) Nukleinsäurenachweisverfahren mittels mehreren Paaren von Donorflurophoren und Quenchemolekülen in derselben Sonde
DE60133472D1 (de) Verfahren und vorrichtung zur herstellung von elektrodenplatten für zellen und diese elektrodenplatten verwendende zelle
WO2001082917A3 (en) Treatment of hypertriglyceridemia and other conditions using lxr modulators
ATE462140T1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
DE602004017283D1 (de) Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
TR199902192T2 (xx) Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties